替奈普酶与阿替普酶治疗急性缺血性卒中患者溶栓时间对临床结局的影响:AcT随机对照试验分析
AcT试验纳入1538例发病4.5小时内急性缺血性卒中患者,比较替奈普酶与阿替普酶。溶栓药物类型未改变发病至溶栓时间或入院至溶栓时间与90天改良Rankin量表0-1分的关联;发病至溶栓每缩短30分钟、入院至溶栓每缩短10分钟,达到90天改良Rankin量表0-1分的概率分别增加1.8%和0.2%。
要点
- 替奈普酶与阿替普酶在时间-结局关联上无显著交互作用(P交互分别为0.161和0.972)。
- 发病至溶栓每缩短30分钟,90天改良Rankin量表0-1分概率增加1.8%。
- 入院至溶栓每缩短10分钟,90天改良Rankin量表0-1分概率增加0.2%。
核心结论
- 替奈普酶给药时间对临床结局的影响与阿替普酶类似,更快给药带来更好的临床结局。
研究设计与样本
- AcT为实用性、注册链接的3期随机对照试验,比较静脉替奈普酶与阿替普酶。
- 纳入年龄>18岁、致残性神经功能缺损、发病4.5小时内且适合溶栓的急性缺血性卒中患者。
- 本分析共纳入1538例患者。
主要发现
- 1146例(74.5%;替奈普酶591例、阿替普酶555例)在3小时内就诊,392例(25.5%;替奈普酶196例、阿替普酶196例)在发病3至4.5小时内就诊。
- 3至4.5小时窗口患者基线美国国立卫生研究院卒中量表评分中位数低于0至3小时窗口(7 vs 10),基线CT血管造影大血管闭塞比例也较低(18.7% vs 26.9%)。
- 替奈普酶与阿替普酶未改变连续发病至溶栓时间(P交互=0.161)或入院至溶栓时间(P交互=0.972)与主要临床结局的关联。
- 无论使用何种溶栓药物,发病至溶栓每缩短30分钟,达到90天改良Rankin量表0-1分的概率增加1.8%。
- 无论使用何种溶栓药物,入院至溶栓每缩短10分钟,达到90天改良Rankin量表0-1分的概率增加0.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The AcT (Alteplase Compared to Tenecteplase) randomized controlled trial showed that tenecteplase is noninferior to alteplase in treating patients with acute ischemic stroke within 4.5 hours of symptom onset. The effect of time to treatment on clinical outcomes with alteplase is well known; however, the nature of this relationship is yet to be described with tenecteplase. We assessed whether the association of time to thrombolysis treatment with clinical outcomes in patients with acute ischemic stroke differs by whether they receive intravenous tenecteplase versus alteplase. METHODS: Patients included were from AcT, a pragmatic, registry-linked, phase 3 randomized controlled trial comparing intravenous tenecteplase to alteplase in patients with acute ischemic stroke. Eligible patients were >18 years old, with disabling neurological deficits, presenting within 4.5 hours of symptom onset, and eligible for thrombolysis. Primary outcome was modified Rankin Scale score 0 to 1 at 90 days. Safety outcomes included 24-hour symptomatic intracerebral hemorrhage and 90-day mortality rates. Mixed-effects logistic regression was used to assess the following: (a) the association of stroke symptom onset to needle time; (b) door (hospital arrival) to needle time with outcomes; and (c) if these associations were modified by type of thrombolytic administered (tenecteplase versus alteplase), after adjusting for age, sex, baseline stroke severity, and site of intracranial occlusion. RESULTS: Of the 1538 patients included in this analysis, 1146 (74.5%; 591 tenecteplase and 555 alteplase) presented within 3 hours versus 392 (25.5%; 196: TNK and 196 alteplase) who presented within 3 to 4.5 hours of symptom onset. Baseline patient characteristics in the 0 to 3 hours versus 3- to 4.5-hour time window were similar, except patients in the 3- to 4.5-hour window had lower median baseline National Institutes of Health Stroke Severity Scale (10 versus 7, respectively) and lower proportion of patients with large vessel occlusion on baseline CT angiography (26.9% versus 18.7%, respectively). Type of thrombolytic agent (tenecteplase versus alteplase) did not modify the association between continuous onset to needle time (Pinteraction=0.161) or door-to-needle time (Pinteraction=0.972) and primary clinical outcome. Irrespective of the thrombolytic agent used, each 30-minute reduction in onset to needle time was associated with a 1.8% increase while every 10 minutes reduction in door-to-needle time was associated with a 0.2% increase in the probability of achieving 90-day modified Rankin Scale score 0 to 1, respectively. CONCLUSIONS: The effect of time to tenecteplase administration on clinical outcomes is like that of alteplase, with faster administration resulting in better clinical outcomes. REGISTRATION: URL: https://classic. CLINICALTRIALS: gov; Unique identifier: NCT03889249.
引用
- Singh N, Almekhlafi MA, Bala F, et al. Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial. Stroke. 2023. PMID: 37800372. doi:10.1161/STROKEAHA.123.044267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。